CD79A and kidney disorder: The updated Kidney Disease: Improving Global Outcomes 2025 guidelines [35] advocate for a ‘two-pronged’ approach to the management of IgAN wherein the focus is to “simultaneously prevent or reduce IgA-containing immune complex formation and IgA-containing immune complex-mediated glomerular injury” and “manage the consequences of existing IgAN-induced nephron loss.” In this context, nefecon and sparsentan belong to the first and second ‘prongs’, respectively.